Evidence map›Paper›PMID 36328585›Full record

ArticleInternal medicine (Tokyo, Japan)2022

Reduced Rate of Disease Flares in Japanese Patients with Systemic Lupus Erythematosus: An Altered Balance between the Use of Glucocorticoids and Immunosuppressants in Recent Decades.

Chihiro Imaizumi, Takehisa Ogura, Yuki Inoue, Yuto Takakura, Takaharu Katagiri, Sayaka Takenaka, Hideki Ito, Kennosuke Mizushina, Ayako Hirata, Hideto Kameda

Open access · diamondAbstract read
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Chihiro ImaizumiDepartment of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan.
Takehisa OguraDivision of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Japan.
Yuki InoueDivision of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Japan.
Yuto TakakuraDivision of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Japan.
Takaharu KatagiriDivision of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Japan.
Sayaka TakenakaDivision of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Japan.
Hideki ItoDivision of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Japan.
Kennosuke MizushinaDivision of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Japan.
Ayako HirataDivision of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Japan.
Hideto KamedaDivision of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Japan.
Toho University · JPAkita University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective This study examined whether or not the disease control in Japanese patients with systemic lupus erythematosus (SLE) had improved in recent years and its possible association with altered balance between the use of glucocorticoids and immunosuppressants. Methods We enrolled Japanese patients with SLE who visited our medical center during 2013-2017 (Group A, 75 patients) and compared them with patients encountered during 1999-2003 (Group B, 69 patients; not overlapping with Group A). Patient background characteristics, doses of glucocorticoids, and the use of immunosuppressants at the times of SLE onset and disease flares were reviewed from the medical records. Disease flare was defined as new British Isles Lupus Assessment Group 2004 A or B scores in at least one system. Results Lupus nephritis and neuropsychiatric manifestations were less frequently observed in Group A than in Group B (p=0.042 and p=0.045, respectively). Although the initial glucocorticoid dosage was similar between the groups, the inclusion rate of immunosuppressants in the initial SLE treatment was significantly higher in Group A than in Group B (56% vs. 6% in Group B, p<0.001). The median number of SLE flares per person-year was significantly lower in Group A than in Group B (0 vs. 0.3, respectively, p<0.001), and a propensity score-matched analysis indicated the association of SLE flare with the non-use of immunosuppressants in the initial treatment (p=0.012). The rates of infectious diseases and other complications were similar between the groups. Conclusion The recent aggressive use of immunosuppressants in Japan resulted in a reduction in the rate of SLE flare.

Indexed as

GlucocorticoidsLupus Erythematosus, SystemicHumansImmunosuppressive AgentsJapanSymptom Flare UpGlucocorticoidsImmunosuppressive Agentsflareglucocorticoidsimmunosuppressantssystemic lupus erythematosustherapeutics

Identifiers

PMID36328585
PMCPMC9683803
OpenAlexW4307877841

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.